Vredenburgh, J., Desjardins, A., Herndon, J. E., Reardon, D., Quinn, J., Sathornsumetee, S., … Friedman, H. (2006). Bevacizumab and irinotecan is an effective treatment for malignant gliomas. In NEURO-ONCOLOGY (Vol. 8, pp. 454–454). Vienna, AUSTRIA: DUKE UNIV PRESS.

Vredenburgh, James, Annick Desjardins, James E. Herndon, David Reardon, Jennifer Quinn, Sith Sathornsumetee, Sridharan Gururangan, Allan Friedman, Darell Bigner, and Henry Friedman. “Bevacizumab and irinotecan is an effective treatment for malignant gliomas.” In NEURO-ONCOLOGY, 8:454–454. DUKE UNIV PRESS, 2006.

Vredenburgh J, Desjardins A, Herndon JE, Reardon D, Quinn J, Sathornsumetee S, et al. Bevacizumab and irinotecan is an effective treatment for malignant gliomas. In: NEURO-ONCOLOGY. DUKE UNIV PRESS; 2006. p. 454–454.

Vredenburgh, James, et al. “Bevacizumab and irinotecan is an effective treatment for malignant gliomas.” NEURO-ONCOLOGY, vol. 8, no. 4, DUKE UNIV PRESS, 2006, pp. 454–454.

Vredenburgh J, Desjardins A, Herndon JE, Reardon D, Quinn J, Sathornsumetee S, Gururangan S, Friedman A, Bigner D, Friedman H. Bevacizumab and irinotecan is an effective treatment for malignant gliomas. NEURO-ONCOLOGY. DUKE UNIV PRESS; 2006. p. 454–454.